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Abstract An 86-year-old man developed a suspected
severe erythroderma during treatment with silodosin (dos-
age unknown) for benign prostatic enlargement. Two
weeks after starting silodosin, he developed a total-body
scaling dermatitis. A biopsy was planned but the patient
improved at his subsequent visit and it was not taken. Si-
lodosin was discontinued and the patient received UVB
phototherapy, clobetasol ointment, and several bland and
protective skin-care measures. One week after the initial
presentation, the patient demonstrated improvement in his
total-body scaling. Based on these findings, the patient was
diagnosed with a suspected silodosin-induced erythro-
derma. Due to limitations in the patient’s clinical history
and investigations, a Naranjo assessment score was not
obtainable.
Key Points
Erythroderma is a complex condition of skin
inflammation that causes total-body scaling and
erythema.
Prescribers should advise patients taking silodosin to
watch for a total-body, coalescing, scaling, and
inflammatory rash.
The development of a total-body, coalescing,
scaling, and inflammatory rash requires immediate
discontinuation and avoidance of silodosin, which
usually allows for a complete recovery.
Background
Silodosin is an a1-adrenoceptor antagonist with high
uroselectivity that is a relatively new medication used for
the treatment of benign prostatic enlargement (BPE) [1].
Current commonly reported adverse effects include a
decrease or absence of semen during intercourse, dizziness,
diarrhea, postural hypotension, headache, swelling of the
throat and nasal passages, and stuffy nose [2]. BPE is one
of the most common conditions associated with aging in
men, affecting as many as 70 % of men aged 61–70 years
and 90 % of men aged 81–90 years [3]. The presence of
any dangerous or complicating adverse effects could
therefore be harmful to a proportion of the elderly popu-
lation. We report a case of a suspected severe silodosin-
induced erythrodermic drug rash. In completing a literature
search through PubMed and MEDLINE using the key-
words ‘‘silodosin’’ and ‘‘erythroderma’’, we found no prior
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report of this adverse drug reaction. To the best of our
knowledge, this is the first time it has been described in the
literature.
Case Presentation
An 86-year-old man presented with a 5-month history of a
severe dermatitis affecting the entire body. The patient was
not in acute distress, but appeared unwell and exhibited
chills. There was no lymphadenopathy present. He denied
any other systemic symptoms. A symmetrical, diffuse
erythema was present with overlying scale covering[90 %
of the body surface area. His skin was warm to the touch.
There was no mucosal membrane involvement. The rash
began in the groin and had since spread to the rest of the
body. It was previously treated with several over-the-
counter creams with no amelioration of symptoms. Silod-
osin had been started for prostatic enlargement 2 weeks
before the rash began. In addition to silodosin, the patient
was taking ramipril, cyclobenzaprine, atorvastatin, rabep-
razole, levothyroxine, meloxicam, hydrocortisone valerate,
an antihistamine of unknown name, ipratropium, and bac-
itracin/polymyxin (exact formulation of Polysporin
unknown). The patient was unable to provide the dosage of
any of his medications. With the exception of silodosin, the
patient did not report having recently started any of his
other medications. Past medical, dermatologic, and family
history was unremarkable. The patient quit smoking
approximately 2 months prior. Figures 1 and 2 are photo-
graphs of the patient’s initial presentation.
Investigations
A biopsy was scheduled to be performed in the week fol-
lowing the patient’s initial visit, but the patient improved
with treatment so it was not performed. No other laboratory
tests were sent off.
Differential Diagnosis
The differential diagnosis included drug-induced erythro-
derma, allergic contact dermatitis, psoriasis, Se´zary syn-
drome, or erythrodermic cutaneous T cell lymphoma. The
latter four are common dermatoses that can eventually pro-
gress to erythroderma. Like an erythrodermic drug reaction,
allergic contact dermatitis can also present as confluent
scales and plaques of erythema, edema, and eventual
lichenification shortly after exposure to an offending agent
[4]. Similarly, acute guttate psoriasis can exhibit scales and
scattered rash-like lesions that tend to coalesce [4]. In
Fig. 1 Initial patient presentation
Fig. 2 Initial patient presentation
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addition, the characteristic shivering, total-body erythema,
and generalized scaling and lichenification of the skin are
also seen in Se´zary syndrome [4]. Finally, like erythroderma,
early cutaneous T cell lymphoma can also present with ill-
defined, scaling patches of erythema [4].
Treatment
Treatment options were discussed and explained to the
patient. Treatment began with an immediate (starting the day
of his presentation)withdrawal of silodosin for 6 weeks.UVB
phototherapy was then provided to accelerate skin healing.
Lasix 40 mg/day for 1 week as well as 18–20 mmHg
compression stockings were given to treat the edema.
The patient was also provided with medications and
guidelines to ease the discomfort of the rash. This included
clobetasol ointment three times daily after a short shower
for 4 weeks for reduction of inflammation and itch, bleach
baths three times per week to prevent secondary impetig-
inization with Staphylococcus aureus ( cup of Javex in
a full lukewarm bath for 10 min followed by a rinse, a pat
dry, application of a moisturizer, and clobetasol); the use of
CeraVe or Cliniderm cleanser and moisturizer for skin
barrier protection and symptomatic relief; hydroxyzine
hydrochloride 25 mg orally in the evening for trouble
sleeping; and cessation of all other creams and shampoos to
lessen the chance of exposure to potential contact allergies.
Based on the patient’s improvement of his total-body
erythroderma within 1 week of implementing the afore-
mentioned treatments, we consider silodosin withdrawal,
topical clobetasol ointment, and UVB treatment an effec-
tive approach to silodosin-induced erythrodermic rash.
Outcome and Follow-Up
One week after the initial presentation, silodosin with-
drawal, and treatment (outlined above), the patient showed
great signs of improvement of his total-body erythroderma.
Figure 3 is a photograph of the patient’s outcome after
1 week.
Discussion
Although a biopsy was not performed for confirmation,
silodosin-induced erythroderma is the most likely diagno-
sis, as none of the patient’s other medications nor the over-
the-counter products could account for his full-body
erythroderma. Given that, with the exception of silodosin,
the patient had not recently started any other medication, it
was most likely that silodosin was the main cause of his
erythroderma. In fact, silodosin had been started 2 weeks
prior to the onset of the patient’s erythroderma. Further-
more, when silodosin was withdrawn and a number of
other symptomatic treatments applied, the erythroderma
demonstrated rapid and significant improvement. Never-
theless, several other causes for the patient’s presentation
and resolution of symptoms remain possible. Firstly, it is
possible that silodosin created a drug–drug interaction with
another medication that the patient was already taking.
Specifically, atorvastatin can increase the level or effect of
silodosin by the P-glycoprotein [multidrug resistance gene
(MDR1)] efflux transporter [5]. Additionally, it is possible
that the patient developed an idiopathic erythroderma that
coincided with the starting of silodosin. Although eryth-
roderma can be idiopathic [4], the temporal link between
the patient’s symptoms and the starting and cessation of
silodosin decrease the likeliness of this explanation.
Finally, it is possible that one or more of the UVB pho-
totherapy or symptomatic treatments (clobetasol ointment,
belch baths, cleanser and moisturizer, hydroxyzine hydro-
chloride) contributed to or caused the patient’s recovery, as
these treatments work as anti-inflammatory, bland, and
protective skin-care measures.
Erythroderma is a condition of inflammation and skin
dysmetabolism that causes total-body scaling and erythema
[6]. It carries a significant risk of morbidity and mortality
even when properly managed, primarily because of its
metabolic burden and complications [6]. An increasing
Fig. 3 One week post-treatment
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incidence of erythroderma may be due to our era’s rising
production of new drugs. Additional drugs linked to
erythroderma include anticonvulsants, antihypertensives,
antibacterials, and calcium channel antagonists [7].
Currently, the pathophysiology of erythroderma is
incompletely understood. It is suggested that an increase in
expression of adhesion molecules (e.g., vascular cell
adhesion protein-1) and their ligands may stimulate
inflammation and increased epidermal proliferation [6, 8].
As well, the interaction of cytokines and adhesion mole-
cules increases the epidermal turnover rate and leads to
additional loss of epidermal cells at the surface [6, 9]. In
our patient, these underlying mechanisms may explain his
presentation, as the exfoliating nature of his rash indicated
increased inflammation as well as epidermal proliferation
and loss at the skin surface. Additionally, our patient’s
malaise and diffuse chills can be attributed to an increased
perfusion in his skin, which caused heat loss, hypothermia,
and a compensatory rise in basal metabolic rate [10].
Erythroderma typically presents as erythematous pat-
ches, which eventually coalesce to produce extensive total-
body erythema [9]. The skin is bright red, scaly, dry, and
warm to the touch, but may also appear thin and glossy [6].
Thickening of the skin due to edema and lichenification
may cause an appearance of skin tightness [6].
The initial management of erythroderma, regardless of
etiology, should include bland and protective skin-care
measures [11, 12], and mid-potency corticosteroids, pref-
erably ointments. For a drug-induced erythrodermic rash,
the most important aspect of treatment is to immediately
discontinue and avoid all precipitants and irritants. Edema
can be treated with diuretics and secondary infections
should be treated with antibacterials. Because erythro-
derma may continue to progress until the underlying cause
is treated, early identification of the etiology is essential to
successful management. In severe cases where there is
notable hemodynamic instability, which was not present in
our current case, the patient should also receive replace-
ment of fluid, electrolyte, and nutrition losses. Although
this is the first case of a suspected silodosin-induced
erythroderma with recovery after drug withdrawal, drug-
induced erythrodermic patients usually recover completely
with prompt diagnosis and treatment [11].
Erythroderma is a complex condition for which the
prognosis depends on the etiology. Drug-induced eryth-
rodermas usually recover completely with prompt diagno-
sis and removal of the offending agent [11]. Although
erythroderma has been attributed to countless drug reac-
tions (e.g., anticonvulsants, antihypertensives), it has never
been described for silodosin. Patients should exercise
caution with its use, particularly when used simultaneously
with atorvastatin, and watch for signs of a total-body,
coalescing, scaling, and inflammatory rash. The develop-
ment of such symptoms requires immediate discontinua-
tion and avoidance of the offending agent.
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